Latest SEC filings, explained by AI. The story behind the numbers.

Eight-tranche U.S. and Canadian senior debt offering to raise $2.99B and C$4.98B net before transaction expenses.

ChampionX drove revenue growth while GAAP earnings slipped; Data Center Solutions revenue rose 76% Y/Y.

Mobility Global’s 1-for-1 spin-off removes it from S&P Global’s consolidated results; pro forma financials recast continuing operations.

Former PwC COO James Flanagan joins Citi’s board and Audit Committee; he will also join Citibank’s board.

Board authorizes $1.2B in additional buybacks after completing prior program; shift from wholesale funding to customer deposits lifts margin.

Bylaw amendments add a one-year net-long holding rule for special-meeting requests and exclusive forums for intracorporate and Securities Act claims.

Onsite power demand broadens beyond hyperscalers as Bloom raises FY2026 revenue guidance to $4.4B–$4.6B

FY2026 gold cost outlook lowered; Nevada Gold Mines deal adds Fourmile, Fiberline and Mike, with $1.95B due to Barrick in Q4.

Exabyte growth and improved pricing fuel sales surge; quarterly dividend raised to $0.175/share

Energy, transportation and raw-material costs pose a $1.4B after-tax FY2027 headwind; organic-sales and EPS growth outlooks hold.

Strong refining drove $6.83B in net income; St. Charles FCC optimization is operational and expected to boost higher-value product capacity.

Higher fuel surcharges drove record railway revenue of $3.53B; productivity gains lifted operating income despite rising fuel costs.

Carload growth and pricing powered gains, but higher fuel prices added 140 bp to Union Pacific’s operating ratio.

Buybacks suspended, with the pause expected through the proposed NBCUniversal and Sky separation; Peacock posted its second straight profitable quarter.

Thorne acquisition updates FY2027 sales outlook to +2% to +4% Y/Y; EPS growth outlook holds despite higher commodity costs.

Lower realized performance revenues and incentive fees weighed on Distributable Earnings despite $63.3B in quarterly inflows.

PAC-3 MSE’s $52.5B award drives record $292B backlog; FY2026 sales, EPS and free cash flow outlooks rise for a second straight quarter.

Building Automation growth, pricing and productivity support raised FY2026 adjusted EPS guidance of $8.40-$8.45.

Board expands to 14 with appointments of Dow’s Jim Fitterling and former KPMG chief Bill Thomas

Higher Super Intelligence spending and lower regulatory credits drive a 56% Y/Y drop in GAAP operating income.

Christopher Garcia will succeed retiring general counsel Richard Rothberg on Feb. 1, 2027; Rothberg will stay through April to assist the transition.

Specialty rental demand and large-project momentum support raised FY2026 revenue guidance of $18.0B–$18.2B.

Software and Infrastructure lead growth; FY2026 free cash flow outlook raised to an increase of >$1B Y/Y.

AI demand and greater device complexity fuel Systems growth and record revenue; December revenue guided to $8.60B ± $400M

LNG exports, power demand and industrial expansion drive project backlog to $14.4B, up $4.7B Q/Q, led by natural gas

Industrial, automotive and data center growth drove revenue up 28% Y/Y; Q4 revenue guided to $5.80B–$6.30B.

Class C recapitalization would deliver a 1:1 non-voting share dividend; a $9.89B state AG settlement charge cut operating profit.

Higher fuel surcharges, volume and pricing lift revenue 12% Y/Y across merchandise, intermodal and coal; rail service weakens.

Higher metal prices drive record Q3 sales despite lower copper volumes; board declares $1.30/share cash and 0.0106 shares/share stock dividends

Global Nutrition business slated for a tax-free spin-off by end-2027, creating a standalone company with ≈$8.5B in annual sales

FPL investment and renewables backlog growth support reaffirmed FY2026 adjusted EPS guidance of $3.92–$4.02, targeting the high end.

Electrophysiology led sales growth as legal settlements weighed on GAAP earnings; FY2026 adjusted EPS guidance narrowed to $5.50–$5.55.

Q3-record daily volume of 29.4M contracts and double-digit volume growth across all six asset classes drove record Q3 revenue of $1.74B.

Pricing and smoke-free volumes lift adjusted earnings; Q4 ZYN investment rises as FY2026 adjusted EPS guidance is set at $8.29-$8.44.

Lower leveraged finance issuance weighed on Moody’s Investors Service; FY2026 adjusted EPS guidance held at $16.50–$17.00.

Record Advanced Connectivity internet adds; 2026 adjusted EPS outlook rises to the $2.40 range and capital investment outlook falls to $23B–$24B.

Growth strategy and PPI execution supported 6% Y/Y organic revenue growth; microbiology business divestiture completed

Carelon growth contrasts with Health Benefits weakness; FY2026 adjusted EPS outlook raised to ≥$29

Improving end markets accelerated core growth outside respiratory testing; FY2026 adjusted EPS guidance rose to $8.57–$8.62.

P&C catastrophe losses rose to $705M from $285M Y/Y, pulling Q3 core operating income lower despite stronger investment income.

Ribbit Capital founder Micky Malka to join Apollo’s board as an independent director, adding technology and financial services expertise.

AI-platform demand lifts preliminary revenue to $18.5B–$19.5B above guidance; customer and product mix boosts gross margin to 12.0%–12.5%

Closed $7.0B in public debt offerings spanning 2030 and 2037 maturities, with floating-rate and fixed-to-floating-rate notes.

Daniel Brennan joins the board and Audit and Finance Committee with a $400K RSU award vesting in October 2027.

Domestic credit card net charge-offs at 3.66%; auto 30+ day performing delinquencies at 4.64%

Discover integration and expected synergies advance as charge-off rates decline

Retail net-lease investment target falls to ≈$1.6B, while FY2026 AFFO/share guidance edges up to $4.58–$4.59

MUFG-led revolving credit facility provides up to $200M to establish and initially capitalize Upstart Bank.

da Vinci antitrust settlement drives a $450M charge and GAAP profit decline despite procedure and lease growth

Slower ad-product rollout cuts FY2026 ad outlook to ≈$2.7B; expected Q4 real-estate closing cuts FCF outlook to ≈$12B

Cloud deals and Cursor/Grok adoption drove Super Intelligence revenue up 830% Y/Y; consumer and enterprise demand lifted Connectivity

Group President Kenneth Canestrari will step down as an executive officer January 31 and retire April 30, 2027, while helping transition responsibilities.

Deal to buy Braze for ≈$5.66B enterprise value adds real-time customer engagement and AI decisioning, with near-term profitability dilution expected.

Deal to sell prenatal testing to Labcorp for $210M cash plus inventory aims to strengthen the balance sheet.

Nasdaq has approved the planned NYSE→Nasdaq listing transfer, with trading expected to begin Nov. 5 under the same HLT ticker.

Authorizes a new $20B multiyear buyback after completing January’s $6B program; raises automotive free cash flow guidance.

Collins Aerospace leads segment profit growth; strong execution lifts FY2026 adjusted EPS outlook to $7.65–$7.75.

Raises FY2026 adjusted EPS guidance to $9.10–$9.15 as margins expand; $1B in litigation and PFAS-exit payments weighs on cash flow.

Higher commercial services volume and pricing lift profit; FY2026 adjusted EPS guidance rises to $8.00–$8.10.

Aeronautics and Defense Systems sales grow; FY2026 MTM-adjusted EPS guidance rises to $29.35–$29.75

Amazon receives a warrant for up to 3.16M shares, with most vesting tied to purchases of 3M optical connectivity and other data center products.

European Commission and New York PSC clear merger hurdles; other regulatory approvals and closing conditions remain outstanding.

MiniMed separation completed after the exchange offer was 5.4x subscribed.

Warrants stop NYSE trading before the Oct. 30, 2026 open and expire worthless unless exercised for $32 cash per share by 5 p.m. ET that day.

Digital credit repurchase authorization rises to $3B as USD Cash funds $193.1M of STRC buybacks

Approved FY2027 executive bonus criteria tie the CEO’s $1.2M base bonus to sales, pre-tax income and environmental and social goals.

Vehicle and eMobility combined into Mobility, prompting a historical segment recast ahead of its planned spin-off.

Develops RNA interference drugs led by CITY-FXI for thrombosis; raises $200M entirely through new shares.

€1.0B senior note issuance funds general corporate purposes, including commercial paper repayment.

Shareholders elect all 12 director nominees, approve executive pay and reject all three shareholder proposals.

Mexico wireless sale and reorganization will eliminate Lori M. Lee’s role as she retires at year-end 2026.

CEO Adair’s 20M-share option award is intended as his only substantive pay for 10 years, subject to shareholder approval.

ACV Auctions acquisition closes at $10.50/share in cash, expanding vehicle remarketing capabilities and footprint.

CFO Jennifer Hamann plans to retire in early 2027 after 35 years at Union Pacific.

Stronger Energy Products margins imply a $4.5B Q/Q earnings lift, partly offset by a $1.3B Upstream drag from lower liquids prices.

STRC daily dividends declared at $1.00/share for November, conditional on stockholder approval and amended certificate effectiveness.

Record $1.10B pre-tax investment income and favorable reserve development lifted earnings despite higher catastrophe losses, mainly from wind and hail.

Higher net interest margin and growth in asset management fees and trading drive record revenue of $7.17B.

Joseph Baratta’s planned retirement will take him off Blackstone’s board on Dec. 31, 2026, shrinking the board from eight directors to seven.

C&I and CRE loan growth lifts interest income; Q4 net interest income guided up ≈4% Q/Q.

AI-driven drug developer raises $150M to advance lead HER2 cancer candidate IAM1363 and its pipeline

Higher customer margin loans and credit balances lift net interest income; quarterly dividend rises from $0.0875 to $0.15/share.

Board expands to add UC San Diego’s Dr. John M. Carethers as an independent director and Public Policy and Sustainability Committee member.

Solar Turbines president Derrick York to succeed Denise Johnson as Resource Industries group president ahead of her retirement.

U.S. Consumer and Small Business card delinquencies edged up in September while principal-only net write-off rates fell.

Lower middle market and private loan appreciation, plus accretive equity issuance, drove a 17th straight quarterly NAV increase.

E-commerce and data-center supply chains drive leasing demand; FY2026 cash same-store NOI growth outlook rises to 7.0%–7.5%

Mark Long replaces David Weigand as CFO, effective October 14, 2026.

Titanium and refractory metal powder maker scales up for defense and aerospace; IPO funding extends runway only into Q2 2027

Management Consulting led Q3 growth; $569M in net Greensill settlement and legal costs weighed on YTD GAAP operating income.

Loan growth and a full quarter of BTIG drive record revenue; FY2026 taxable-equivalent revenue growth outlook raised to 8%–9% Y/Y

Commercial loan growth lifted net interest income, but fading Visa and capital-markets activity drove revenue down 5% Q/Q.

Corporate Trust growth and higher collateral balances drive platform gains; reinvestment at higher yields lifts net interest income.

Quarterly cash dividend of $1.47/share declared, payable Nov. 13 to shareholders of record Oct. 30.

September’s combined ratio improved to 90.0% from 100.4% Y/Y; Q3 profit slipped despite premium growth.

Equity strength and record Wealth Management revenue fuel growth; carried-interest reversal drags Investment Management.

BSA/AML and sanctions consent orders triggered a $1.2B penalty charge; loan growth and fixed-rate asset repricing lifted net interest income.

Plans ≈$8B in FY27 acquisitions as acquired businesses’ revenue contribution is expected to rise

iShares-led net inflows of $205B supported fee growth; a $564M noncash charge tied to GIP and HPS weighed on GAAP earnings.

At-the-market offering allows an additional $500M in common share sales at management’s discretion.

VAC’s estimated $1.786B acquisition terms are amended to address e-VAC’s customer-contract dispute, debt repayment and price adjustments.

Cressey & Company’s Paul J. Diaz joins the board and its Audit and Research Committees effective Nov. 1, 2026.

Services and Wealth lead growth as Citi pulls investment forward toward its 11%-13% near-term RoTCE (non-GAAP) target

Quarterly dividend declared at $1.09/share on common and Series A and B ESOP preferred stock, payable on or after Nov. 16.

Talc litigation drives a $5.52B pre-tax adjustment; strong operations lift FY2026 adjusted EPS guidance to $11.05-$11.15

Repurchased $192.4M of STRC preferred shares while MSTR ATM sales funded most of a $21.5M bitcoin purchase.

Vylor separation challenge prompts Corteva to hold off on dividends and buybacks pending appeal, despite a stay of court restrictions.

Develops NanO₂ intravenous oxygen therapy for glioblastoma; IPO funds trials but not the full path to approval

Green-bond issuance through Digital Euro Finco totals €1.0B to finance or refinance eligible green projects.

Develops superconducting control chips for quantum computers; commercialized products supplied ≈5% of FY2025 revenue.

Extends $3.0B senior unsecured revolver by one year to 10/24/2030, with all other terms unchanged.

RNA interference drug developer seeks $165M–$185M gross to fund CITY-FXI trials and early-stage pipeline development

Fed and OCC consent orders resolve financial-crimes compliance reviews, with a $350M AENB penalty and FY2026 guidance unchanged

Makes specialty metal powders for defense and aerospace; H1 2026 revenue grew 507% Y/Y, but gross margins stayed negative.

AI-guided drug developer uses automated labs; proceeds chiefly fund brain-penetrant HER2 inhibitor IAM1363

Danny Deep becomes CEO on Jan. 1, 2027, as Phebe Novakovic transitions to Executive Chairman.

Cost pressures lower FY2026 core EPS growth guidance to +2.5%–3.5%; more structural cost cuts planned to fund innovation and improve North America.

Vylor completes $1.439B EIDP note exchange; indenture amendments modify noteholder rights across all three series.

UniFirst merger partners certify FTC request compliance; closing barred before Dec. 11 unless the FTC ends its investigation early

Priced €1.0B of euro notes at a 5.125% coupon, with proceeds intended to finance or refinance eligible green projects.

Closed CHF510M senior unsecured bond offering to fund or refinance projects under its Green Bond Framework.

Hess Midstream stake and DJ Basin asset transfers are expected to cut Bakken unit midstream costs ≈50%, with a $3B–$4B after-tax loss at closing.

Proposed settlement of political-influence derivative claims would bring $15.5M from D&O insurers and governance reforms, subject to court approval.

Paramount Skydance merger closes at $31.02 per WBD share in cash; WBD exits Nasdaq and plans to end SEC reporting.

President and COO Spencer Stiles will succeed Kevin Lobo as CEO on Jan. 1, 2027; Lobo will become Executive Chair.

McKesson plans ≈$1.4B minority stake in Option Care Health’s $32.05/share take-private with CD&R, targeting community specialty care.

Seed segment spun off as Vylor, now trading independently on the NYSE under VYLR

Launched a $1B accelerated share repurchase with JPMorgan Chase, with final settlement due by Jan. 5, 2027.

New Energies chief Jeff Gustavson becomes CFO as Eimear Bonner moves to lead Oil, Products & Gas, effective Jan. 1, 2027.

Tax-allowance release cuts estimated Q3 deferred tax expense to $1.88B on a $20.9B digital-asset gain

Stockholders elected Class II directors, backed executive pay and ratified Frost, PLLC as FY2027 auditor.

Seed spin-off completed with Vylor distributed to shareholders, leaving New Corteva as a standalone Crop Protection business

Performance Technologies’ ≈$946M divestiture to Gentherm closes; Modine uses ≈$156M cash proceeds to repay borrowings

Pace overhaul targets ≈$2.5B in cumulative savings before charges and reinvestment through FY2031, with ≈$1.0B in expected pre-tax charges.

Seed business spun off as Vylor via a pro rata share distribution; VYLR expected to begin NYSE trading Oct. 1.

STRC keeps its 12% annual dividend rate; planned daily payouts hinge on stockholder approval and amended certificate effectiveness.

Builds data-center power and modular infrastructure; Olympus retains 85% of voting power after the offering.

District Court denies California’s bid to block Vylor seed spinoff; share distribution expected Oct. 1.

Korea’s non-binding framework outlines up to $120B for U.S. reactors and a 5%–10% cornerstone equity stake in Westinghouse.

10-year CEO and chief scientific officer equity awards replace annual grants through 2036, tying payouts to new-product revenue and pipeline milestones.

AI demand drives higher networking growth targets; Juniper annual synergy goal rises to $800M by FY2028-end.

Outside-director annual equity awards rise $20,000 to $215,000; shareholders reject an independent board chair.

South Korean wireless fire-detection supplier enters a direct listing after FY2025 revenue fell 72.1% Y/Y as construction projects stalled.

Agreed to buy World Labs Technologies for ≈$8.2B in AMD stock, with dilution tied to AMD’s share price near closing.

Common-stock ATM sales raised $246M to fund bitcoin purchases and STRC preferred-stock repurchases.

Sells catheter-delivered devices to close holes in the heart; IPO triggers a $7M technology license outside its core business

Develops siRNA drugs for hereditary angioedema and other diseases; $446M all-primary raise funds clinical development

Business discussion set for Wolfe Research Utilities, Midstream & Clean Energy Conference, with live and on-demand webcast.

Quarterly dividend declared at $0.06 per share, payable 10/29/2026 to holders of record 10/9/2026.

RegenKit platelet-rich plasma kit maker faces an October debt maturity exceeding cash despite MiMedx-led U.S. wound-care growth.

Series G non-voting convertible preferred stock provisions were removed from the corporate charter.

Daily dividends proposed for STRF, STRC, STRK and STRD, subject to stockholder approval; rates and total regular dividends would stay unchanged.

Develops gene-silencing RNA medicines; Biogen collaboration drove FY2025 revenue growth of 388% Y/Y.

Jeffrey Hibbard to succeed retiring CFO Ann Janssen; future restricted-stock and RSU grants switch from cliff to ratable vesting

Back to Starbucks targets ≈250 underperforming North America stores for closure, triggering ≈$300M in charges and lowering FY2026 global opening plans.

Hair and nail products seller behind OPI and Clairol goes public with KKR retaining majority voting control.

DoW provides $3.7M in non-dilutive funding for AP-SA02’s Phase 3 study, planned to begin in H2 2026.

Agreed to buy 50% of Sandals and Beaches Resorts for ≈$3.0B in cash, expanding into all-inclusive resorts.

Connects patients with physicians for medical-cannabis certifications; FY2025 revenue fell 34.9% Y/Y as state restrictions hit consultations

Realized performance revenues drive ≈90% of the >$350M preliminary Q3 realization estimate, which includes some expected quarter-end income.

Series F preferred stock fully redeemed; related charter provisions eliminated

Develops quantum control and readout chips; seeks capital after losing $64.9M in merger-contingent funding.

Power and AI data-center developer faces ≈$178B of backlog-linked construction spending under SoftBank control

USD Cash funded $75.7M in bitcoin purchases and $174.0M in STRC preferred-stock repurchases.

Athene posts September 2026 update on asset risk and stress considerations.

Sells smart rings and health memberships; most offering proceeds go to existing holders and employee-equity taxes

Fee-driven homeowners insurer; founder Kenneth Gregg retains 93.9% voting power after the offering

OK.de webmail ads and referral services; Jensen- and Dartsch-controlled holders retain 72% of post-offering votes.

Political campaign texting platform registers existing shares for resale; proceeds go entirely to selling holders.

Develops antibodies to remove disease-driving immune cells; $350M all-primary raise funds ipsoprubart’s registrational trials

Reincorporation from Delaware to Nevada takes effect, changing certain stockholder rights under Nevada law and new charter and bylaws.

Makes specialty metal powders and parts for defense and aerospace; H1 2026 revenue grew 507% Y/Y with negative gross margins.

Quarterly dividend raised 8.8% to $1.60 per share, extending annual increases since going public

Lower overlapping ownership prompts a Gentherm exchange-ratio adjustment; Performance Technologies’ cash payout to Modine falls to $159M.

Quarterly common dividend held at $0.45 per share; Board reaffirms that level through year-end 2026.

Planned 7% quarterly dividend hike to $1.52/share reflects commitment to return all free cash flow to owners over time.

Agentforce strategy bets on AI-driven customer expansion, alongside a record $25B accelerated share repurchase.

Develops NanO2 to deliver oxygen to hypoxic tissue; offering repairs the balance sheet and funds glioblastoma and respiratory trials.

Pay review adjusts annual base salaries to $755K for CTO Alper Ilkbahar and $618K for legal chief Bernard Shek; Shek’s incentive target also changes.

Barclays Global Financial Services Conference presentation set for Sept. 16, with a live webcast and replay through at least Sept. 30.

Cold-pressed juice seller seeks expansion funding after FY2025 revenue fell 28.3% Y/Y despite lower production costs.

Bought-deal common share offering closed with ≈CDN$3.0B in gross proceeds, including a fully exercised over-allotment option.

Repurchased $139.3M of STRC preferred stock using USD Cash.

FDA grants AP-SA02 Breakthrough Therapy designation for complicated S. aureus bacteremia to expedite development and review.

California homeowners-insurance underwriter earns commissions; offering proceeds go entirely to existing holders

Brookfield Asset Management and Brookfield Corporation will hold separate Investor Day events in New York on Sept. 17, 2026, with webcasts and replays.

Established an at-the-market equity program with Goldman Sachs to sell up to $2.0B in shares for general corporate purposes.

New $1.0B at-the-market stock program replaces the prior agreement after ≈$1.0B in share sales.

Shareholders approved 16 million more Class B shares for the employee stock purchase plan.

Common and Series I preferred units are set to move from NYSE to TXSE on Oct. 5, with tickers unchanged.

Declared a $2.00/share cash dividend, payable 10/15/2026 to stockholders of record 9/30/2026.

CDN$2.6B bought-deal share offering to partly fund announced acquisitions and provide flexibility for potential growth opportunities

Agrees to buy Tallgrass Energy’s crude oil business for $2.55B cash, adding connections from the Bakken, Powder River and DJ basins through Cushing.

Share buyback authorization increased by $2.0B to $20B; repurchases remain discretionary

Jack Tobin postpones retirement to succeed Lynne Fitzpatrick as CFO when she becomes CEO in March 2027.

Anil Chakravarthy will succeed Shantanu Narayen as CEO on Dec. 1, 2026; Narayen becomes Executive Chair.

CEO Matt Flannery and CFO Ted Grace will present at Morgan Stanley’s Laguna Conference on 9/15/2026.

Leaders will discuss strategy, recent results and end-market expectations at the Wells Fargo Healthcare Conference.

Greg Ebel will retire as CEO at year-end; Michele Harradence takes over Jan. 1, 2027 following a multi-year succession process.

Amazon server collaboration includes a warrant for up to 25 million Qualcomm shares, with further vesting tied to commitments, orders and purchases.

Doubled preferred-securities repurchase authorization to $2.0B and used $176.3M of USD Cash to buy back STRC shares.

Cyber incident disrupts global manufacturing and order shipments; Q3 and FY2026 sales growth and adjusted EPS guidance now unlikely to be met

Nuclear equipment and spent-fuel supplier pursuing Palisades restart; founder-affiliated holders retain 99% of post-IPO votes.

Nuclear Liabilities Fund awards Brookfield a multi-decade mandate with an initial $1B commitment to support UK nuclear decommissioning.

CFO Edward Schlesinger to discuss Springboard progress and demand drivers at upcoming investor conference

Approved executive deferral plan allows deferring up to 75% of base salary and 90% of annual performance bonus; obligations are unsecured and unfunded.

2-for-1 stock split completed; Q3 dividend adjusted to $0.125 per share, payable October 14

Barclays Energy-Power Conference presentation on Sept. 9 will cover business and affairs, with a live and on-demand webcast.

Shareholders approve stock issuance for pending Dominion Energy merger and raise authorized common shares to 5.0B.

Jessica Uhl set to succeed Peter Osvaldik as CFO in February 2027; 2026 guidance reaffirmed.

Closed ≈$10.9B Apogee acquisition, adding late-stage zumilokibart for atopic dermatitis and an asthma combination candidate

Board declares $0.0625 quarterly cash dividend per Class A share, payable 9/24/2026.

Series M preferred stock fully redeemed; Certificate of Elimination removes the series from the charter.

Property-management software and payment processing; Silver Lake retains majority voting control.

Menswear and formalwear rental retailer behind Men’s Wearhouse; offering funds debt repayment after shareholder payouts.

Sells microphones and on-device AI chips; acquired Knowles operations supplied 97% of FY2025 revenue.

Common-stock ATM sales funded bitcoin purchases and STRC preferred buybacks.

Sale of USI Insurance Services to Aon is the focus of the posted presentation.

Australian Strategic Materials acquisition closes, with holders receiving Energy Fuels equity and cash.

Charter amendment extends voting and ownership limits to SBSEFs and expands SEC review of charter changes while ICE controls an SBSEF.

Completed the $5.0B all-cash Indicor Instrumentation acquisition, adding recurring-revenue businesses expected to modestly lift 2026 adjusted earnings.

Cybersecurity incident disrupts global operations, limiting access to systems used to process and ship customer orders.

Mailchimp becomes a separate segment in FY2027; non-GAAP earnings will begin including share-based compensation.

FDA extends Deramiocel review to assess new HOPE-3 data; Capricor seeks an indication focused on upper limb function.

Cigarette manufacturing pact links PMI’s non-U.S. affiliates with Altria’s Philip Morris USA as PMI continues its smoke-free focus.

Utility-scale solar and storage builder has only 15.6% of June 2026 backlog under signed contracts

Board adopts severance protections for SVPs and above, including larger change-in-control payouts, and updates bylaws for Delaware law.

Shareholders elected directors through 2029, backed advisory say-on-pay and ratified KPMG as auditor.

Vylor secures consent to remove most restrictive EIDP note covenants and change-of-control repurchase provisions, contingent on exchange settlement and Corteva’s separation.

Defense sensors and mission software supplier; company IPO proceeds chiefly repay lenders rather than fund expansion.

Google custom silicon partnership ties most warrant vesting to Google-related purchases of AI inference, storage and networking products.

Supplies pharmaceutical intermediates from Chinese manufacturers; existing holders retain 98.5% of post-IPO votes

MSTR ATM sales funded STRC dividends and buybacks, with remaining proceeds added to the USD reserve.

Stockholders approved below-NAV common share issuance authority, subject to board approval and issuance limits.

Makes copper foil for batteries and electronics; chairman Guanran Wang retains 51.3% control after the offering.

Solar-project developer commercializing solar-powered autonomous mowers; Cywinski founders retain 96.55% of post-IPO voting power.

Japanese earned-wage-access platform FUKUPE depends on one customer for 93.6% of FY2026 revenue

Developing oral mizagliflozin for post-bariatric hypoglycemia; $81.3M gross raise funds Phase 2 trials.

Networking led product growth as hyperscaler AI infrastructure demand rose; product orders also grew strongly beyond hyperscalers.

Develops oral Nav1.8 non-opioid pain drugs; $346M all-primary raise backs LTG-001 pivotal trials and LTG-321 chronic-pain studies.

Develops small-molecule cancer drugs; $150M all-primary raise funds trials led by BH-30643 for treatment-resistant lung cancer.

Chilean ticketing and event-services provider; chair Yethro Dinamarca Santelices retains 61.7% ownership after the offering

Develops BHB-1893, an oral cardiac myosin inhibitor for hypertrophic cardiomyopathy; $383M all-primary raise funds Phase 3 trials.

Two-for-one stock split approved; Q3 adjusted EPS guidance restated on a post-split basis

Develops immune-disease biologics using ATTOBODY; $289M all-primary raise backs clinical validation of itch treatment ATTO-1310.

Rescission offer seeks to unwind acquisitions of General Dynamics common shares.

Third-party cloud data theft deemed material due to file volume and potential sensitivity, including proprietary and patient health information

Develops Oxnimbi, a once-nightly sleep apnea pill; $192M all-primary raise funds regulatory work and launch if approved.

Tokenizes securities on blockchains; post-merger resale registration covers 92.8% of issued shares.

Sandwich-chain franchisor; Blackstone retains 65.2% of post-IPO voting power

Premium womenswear brand positioned on sustainability; offering proceeds mainly repay debt following a shareholder dividend.

Higher unit volume drove MedSurg/Neurotechnology and Orthopaedics growth; cyber recovery progressed and FY2026 guidance narrowed.

FDA panel finds Deramiocel evidence insufficient for DMD cardiomyopathy, a narrower indication than proposed; vote is non-binding

Unauthorized access led to file exfiltration without disrupting operations; a separate reported cyber matter is under review

Brazilian rare-earth explorer targets Itarantim’s entirely inferred resources at a $526M implied IPO valuation.

HOPE-3 model update leaves Deramiocel’s LVEF result no longer statistically significant; primary efficacy endpoint is unchanged.

Converts former Celsius bitcoin mines into AI infrastructure for sole tenant Nscale; direct listing sells existing holders’ shares

Announced merger would end EY’s independence, prompting AES to replace it with KPMG for FY2026.

Develops CRISPR medicines to lower cholesterol; $129M all-primary raise funds STX-1150 trials and pipeline development.

Massachusetts–Rhode Island community lender BayCoast Bank goes public with its mutual parent retaining 55% voting control.

Sells data-center space, power and connectivity; nearly all of the $1.05B raise repays debt, with Brookfield retaining control

TRISO nuclear fuel maker for advanced reactors is valued at 768× FY2025 revenue

Ransomware attack on fairlife’s systems temporarily halts U.S. production; investigation and restoration are ongoing.

GPU cloud and crypto hosting provider pivots toward AI infrastructure; shareholders sell through a direct listing

Develops continuous-delivery lenalidomide for multiple myeloma; IPO funds trials, but approval requires further capital

FDA agrees to AP-SA02 pediatric development plan; the pediatric study is deferred until adult safety and efficacy data are available.

2-for-1 stock split via a stock dividend; split-adjusted trading expected to begin 8/11/2026

Agreement to buy Crinetics for $85/share in cash would add PALSONIFY and late-stage endocrine medicines

Bitcoin sales funded preferred-stock distributions and replenished the USD reserve.

Redomiciliation merger moves shareholders to Texas-governed ExxonMobil Holdings while preserving their ownership stakes.

Sells launches, Starlink subscriptions and AI services; $75B all-primary raise funds compute and space infrastructure

FDA Fast Track for AP-SA02 enables rolling BLA review as Armata plans a Phase 3 superiority study in S. aureus bacteremia.

ironSource Ads Network shutdown and a potential Supersonic sale aim to accelerate revenue growth and lift margins.

Convertible-loan fair-value losses drove the net loss; Innoviva credit maturities were extended amid a going-concern warning.

FDA grants AP-SA02 QIDP status and confirms Phase 2a data support Phase 3; trial start planned for H2 2026.

WBD ends Netflix merger after deeming Paramount Skydance’s bid superior; Netflix declines to revise its offer.

FDA QIDP designation makes AP-SA02 eligible for extended exclusivity and Fast Track; Phase 3 superiority study planned for H2 2026.

Kyowa Kirin license and collaboration agreement will terminate upon regulatory approval.

Planned Performance Technologies spin-off and merger with Gentherm would leave Modine focused on Climate Solutions.